Skip to content
  • About
  • Board
  • News
  • Sign Up
  • Contact

Visit

vjoncology logo
VJHemOnc
Logo
  • Home (current)
  • Diseases
    CLL
    Multiple Myeloma
    Myeloproliferative Neoplasms
    ALL
    AML
    Lymphoma
    View all Diseases
  • Topics
    Transplantation
    Measurable Residual Disease
    CAR-T & Cellular Therapy
    Pharmacy
    Nursing
    Supportive Care
    View all Topics
  • Conferences
    ASH
    2019
    MPN Advances Day
    2019
    iwCAR-T
    2019
    COSTEM
    2019
    ESMO
    2019
    iwCLL
    2019
    View all Conferences
  • Features
  • Podcasts
    • About
    • Board
    • News
    • Sign Up
    • Contact

EBMT 2017

4:58
Concerns about using social media in oncology
Naveen Pemmaraju
1:47
Predicting and preventing clonal evolution in multiple myeloma
Irene Ghobrial
1:24
Only the beginning of precision medicine and multiple myeloma.
Irene Ghobrial
1:26
Cellular therapy: a key part of EBMT 2017
Nicolaus Kröger
3:14
Advantages of chemotherapy and hypomethylating agents in myelodysplastic syndrome
Maria Teresa Voso
4:01
Allogeneic transplant is not the quintessential treatment for ALL anymore!
Sebastian Giebel
1:24
Treatment methods in mantle cell lymphoma
Stephen Robinson
2:05
Autologous stem cell transplantations: BEAM or BEAC?
Stephen Robinson
2:00
Updates on treatment methods for Hodgkin Lymphoma
Stephen Robinson
3:26
What are the differences in health technology assessment (HTA) across Europe?
Jean-Luc Harousseau
6:43
How can clinicians and nurses care for patients with oral graft-versus-host disease (GvHD)?
Nathaniel Treister
2:36
Transplantation versus novel therapies in high-risk chronic lymphoblastic leukemia (CLL)?
John Gribben
2:40
Can the cytomegalovirus be predicted by ELISpot assays?
Roy Chemaly
2:19
Highlights from the EBMT 2017 cell therapy day
Christian Chabannon
1:50
Waldenström’s macroglobulinemia: Treatment methods and clonal evolution
Irene Ghobrial
3:44
Is double autologous transplantation in multiple myeloma superior in the age of new agents?
Jean-Luc Harousseau
  • 1
  • 2
  • 3
  • Next
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Continue

Please enter your details if you would like to receive the latest hemonc news and updates

Sign up
Disease Channels
  • CLL
  • Multiple Myeloma
  • Myeloproliferative Neoplasms
  • ALL
  • AML
  • Lymphoma
  • View all
Join our community

Keep up-to-date via social media

Sign up for email updates

Get great new content delivered to your inbox

Sign up
mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJHemOnc logo
The content of VJHemOnc is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy